Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.
Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, Kinloch S, Babiker A, Weber J, Nwokolo N, Fox J, Fidler S, Phillips R, Frater J; SPARTAC and CHERUB Investigators. Hoffmann M, et al. Among authors: fisher m. PLoS Pathog. 2016 Jul 14;12(7):e1005661. doi: 10.1371/journal.ppat.1005661. eCollection 2016 Jul. PLoS Pathog. 2016. PMID: 27415828 Free PMC article. Clinical Trial.
HIV-1 DNA predicts disease progression and post-treatment virological control.
Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators. Williams JP, et al. Among authors: fisher m. Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821. Elife. 2014. PMID: 25217531 Free PMC article.
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.
Hurst J, Hoffmann M, Pace M, Williams JP, Thornhill J, Hamlyn E, Meyerowitz J, Willberg C, Koelsch KK, Robinson N, Brown H, Fisher M, Kinloch S, Cooper DA, Schechter M, Tambussi G, Fidler S, Babiker A, Weber J, Kelleher AD, Phillips RE, Frater J. Hurst J, et al. Among authors: fisher m. Nat Commun. 2015 Oct 9;6:8495. doi: 10.1038/ncomms9495. Nat Commun. 2015. PMID: 26449164 Free PMC article. Clinical Trial.
Short-course antiretroviral therapy in primary HIV infection.
SPARTAC Trial Investigators; Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A. SPARTAC Trial Investigators, et al. Among authors: fisher m. N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039. N Engl J Med. 2013. PMID: 23323897 Free PMC article. Clinical Trial.
The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.
Inshaw J, Leen C, Fisher M, Gilson R, Hawkins D, Collins S, Fox J, McLean K, Fidler S, Phillips A, Lattimore S, Babiker A, Porter K; UK HIV Seroconverters Cohort. Inshaw J, et al. Among authors: fisher m. PLoS One. 2015 Jul 30;10(7):e0132772. doi: 10.1371/journal.pone.0132772. eCollection 2015. PLoS One. 2015. PMID: 26225723 Free PMC article.
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.
Yang H, Llano A, Cedeño S, von Delft A, Corcuera A, Gillespie GM, Knox A, Leneghan DB, Frater J, Stöhr W, Fidler S, Mothe B, Mak J, Brander C, Ternette N, Dorrell L; Research in Viral Eradication of Reservoirs (RIVER) trial study group. Yang H, et al. Cell Rep. 2021 May 11;35(6):109103. doi: 10.1016/j.celrep.2021.109103. Cell Rep. 2021. PMID: 33979627 Free article.
Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort.
Granger LA, Huettner I, Debeljak F, Kaleebu P, Schechter M, Tambussi G, Weber J, Miro JM, Phillips R, Babiker A, Cooper DA, Fisher M, Ramjee G, Fidler S, Frater J, Fox J, Doores KJ. Granger LA, et al. Among authors: fisher m. AIDS. 2021 Nov 1;35(13):2073-2084. doi: 10.1097/QAD.0000000000002988. AIDS. 2021. PMID: 34127581 Free PMC article.
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ, Winston A, Fox J, Orkin C, Herieka EA, Ainsworth JG, Post FA, Wansbrough-Jones M, Kelleher P; Hydroxychloroquine Trial Team. Paton NI, et al. Among authors: fisher mj. JAMA. 2012 Jul 25;308(4):353-61. doi: 10.1001/jama.2012.6936. JAMA. 2012. PMID: 22820788 Free PMC article. Clinical Trial.
5,589 results